Celldex will present Phase 2 study data on barzolvolimab for chronic spontaneous urticaria at EAACI Congress 2025.
Quiver AI Summary
Celldex announced the upcoming presentation of data from its Phase 2 study of barzolvolimab in chronic spontaneous urticaria at the EAACI Congress 2025 in Glasgow, Scotland. Abstracts will be available online starting June 12th, and the company will host a webcast the same day to discuss the findings. Key presentations include an oral session on June 13th focusing on sustained disease control after withdrawal of barzolvolimab, and another on June 14th discussing improvements in angioedema over 52 weeks of treatment. Celldex aims to develop innovative therapies targeting disorders related to allergies, inflammation, and autoimmunity.
Potential Positives
- Data from Celldex's Phase 2 study of barzolvolimab will be presented at a prestigious international conference, enhancing the company's visibility and credibility in the field of immunology.
- The company is engaging with key stakeholders through a webcast and conference call, promoting transparency and direct communication regarding their research findings.
- The presentation of late-breaking oral abstracts indicates that Celldex's research is considered significant and timely, underscoring the potential impact of their findings on chronic spontaneous urticaria treatment.
Potential Negatives
- Presentation of Phase 2 study results may suggest that the company is still in the early stages of developing its treatment for chronic spontaneous urticaria, indicating a longer timeframe before potential commercialization.
- The timing of the webcast and abstract release may lead to confusion or concerns among investors if the data does not meet expectations, potentially impacting stock performance.
- There is no mention of successful outcomes from the Phase 2 study, which could leave room for uncertainty about the efficacy of barzolvolimab in treating chronic spontaneous urticaria.
FAQ
What is the purpose of the Phase 2 study of barzolvolimab?
The Phase 2 study evaluates the efficacy and tolerability of barzolvolimab in patients with chronic spontaneous urticaria (CSU).
When will the data from the study be presented?
The data will be presented at the EAACI Congress on June 13, 2025.
How can I access the webcast on barzolvolimab?
You can register for the webcast on the Investor Relations page of Celldex's website.
Who will present the findings at the EAACI Congress?
Dr. Ana Maria Giménez-Arnau and Dr. Martin Metz will present key findings during the sessions.
What are the key topics covered in the presentations?
The presentations will focus on sustained disease control and improvements in angioedema in CSU patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLDX Hedge Fund Activity
We have seen 87 institutional investors add shares of $CLDX stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COMMODORE CAPITAL LP added 3,200,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $58,079,999
- JEFFERIES FINANCIAL GROUP INC. removed 2,335,398 shares (-97.7%) from their portfolio in Q1 2025, for an estimated $42,387,473
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,697,498 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $30,809,588
- KYNAM CAPITAL MANAGEMENT, LP added 1,435,793 shares (+28.4%) to their portfolio in Q1 2025, for an estimated $26,059,642
- JENNISON ASSOCIATES LLC removed 1,324,410 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $33,467,840
- UBS GROUP AG added 1,078,443 shares (+276.7%) to their portfolio in Q1 2025, for an estimated $19,573,740
- LOGOS GLOBAL MANAGEMENT LP removed 900,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $22,743,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLDX Analyst Ratings
Wall Street analysts have issued reports on $CLDX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 03/20/2025
- Citigroup issued a "Buy" rating on 01/08/2025
To track analyst ratings and price targets for $CLDX, check out Quiver Quantitative's $CLDX forecast page.
Full Release
HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12 th at 6:01 pm ET/ Friday, June 13 th at 12:01 am CEST. Celldex will host a webcast on Thursday, June 12 th at 6:00 pm ET to discuss the data.
Phase 2 CSU 76 Week Efficacy and Tolerability Data
Company Webcast and Conference Call
Date & Time:
Thursday, June 12th at 6:00 pm ET/11:00 pm BST
Presenters:
Company representatives and Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU study
Webcast Access:
Please visit the Events section on the Investor Relations page of
Celldex's website
to register for the webcast. Parties interested in participating via telephone may register
here
to receive the dial-in numbers and unique PIN to seamlessly access the call.
EAACI Presentation Session
Date & Time:
Friday, June 13
th
at 9:12 am BST/4:12 am ET
Late Breaking Oral Presentation 100227:
Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Presenting Author:
Ana Maria Giménez-Arnau, MD, PhD, Associate Professor of Dermatology
Autonomous University and Pompeu Fabra University
Phase 2 CSU 52 Week Angioedema Data
EAACI Session Date & Time:
Saturday, June 14
th
at 3:48 pm BST/10:48 am ET
Oral Presentation 000588:
Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of Treatment
Presenting Author:
Martin Metz, MD, Professor, Department of Dermatology and Allergy, Head of Translation Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and lead investigator for the Phase 2 CSU study
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit
www.celldex.com
.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
[email protected]
Patrick Till
Meru Advisors
(484) 788-8560
[email protected]
